IRCT20190628044046N1 IRCT 2020-03-12 Tehran University of Medical Sciences Effect of Carvedilol on Reducing Transtosomab Cardiac Complications Determining the Preventive Effect of Carvedilol on Reducing Transtosomab Cardiac Complications in Patients With Early Stages of HER2-Breast Cancer 2019-06-26 anticipated 60 Complete https://irct.ir/trial/40580 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple individual randomization, without stratification, produced by Excel (Microsoft office) (using "Generate random number" order and "if") and providing a table of A(intervention) and B(control) sequence. # =randbetween(1-60) #save as "value" #copy for 60 rows # =if (A1>MEDIAN(A1:A60), 1,0) #copy for 60 rows #Replace "1" by "A"in all #Replace "0" by "B"in all, Blinding description: The main outcome(LVEF) assessor(Echo-man) is not aware of intervention groups. 3 Trastuzumab related cardiomyopathy. Intervention 1: Intervention group: Carvedilol drug with 3.125 mg twice daily and then increasing the dose weekly up to 12.5 mg or up to the tolerance. Intervention 2: Control group: Not taking Carvedilol (Routine care). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information